Showing 1021-1030 of 1604 results for "".
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Study Reveals Novel Insights on Melanin Formationhttps://practicaldermatology.com/news/study-reveals-novel-insights-on-melanin-formation/2461491/“Nrf3” regulates the process of melanin production in mouse and human cells, a new study shows. NF-E2-related factor 3 or “Nrf3,” a known transcription factor, or protein involved in the pro
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D arr
- Beekman 1802 Pledges to Put Nurses First in 2023https://practicaldermatology.com/news/beekman-1802-pledges-to-put-nurses-first-in-2023/2461487/Beekman 1802 is launching "
- Soligenix Initiates Phase 2 Trial of SGX302 for Mild to Moderate Psoriasishttps://practicaldermatology.com/news/soligenix-initiates-phase-2-trial-of-sgx302-for-mild-to-moderate-psoriasis/2461471/Patient enrollment has been opened for Soligenix, Inc.'s Phase 2a study evaluating SGX302 (synthetic hypericin) for the treatment of mild to moderate psoriasis. "We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psor
- Zubin Meshginpoosh Named President and COO at Sentéhttps://practicaldermatology.com/news/zubin-meshginpoosh-named-president-and-coo-at-sente/2461463/Zubin Meshginpoosh is now the President and Chief Operational Officer of Senté. "Zubin has an incredible track record for enabling teams to achieve success in high growth and fast-changing environments," says Faheem Hasnain, Chairman of the Board at Senté, in a n
- Garnier Debuts Product Impact Ranking Across Hair Care Rangehttps://practicaldermatology.com/news/garnier-debuts-product-impact-ranking-across-hair-care-range/2461455/Garnier is launching a digital labeling system that ranks its hair care products versus other L'Oreal Group Products based on 14 environmental factors. Product Impact Labelling ranks each product from A to E, with "A" indicating the 10% of L'Oreal Group Products in the
- Almirall Joins Project Aimed at Giving Clinical Trial Data Back to Study Participantshttps://practicaldermatology.com/news/almirall-joins-project-aimed-at-giving-clinical-trial-data-back-to-study-participants/2461446/Almirall is participating in FACILITATE (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem), a patient-driven Innovative Medicines Initiative (IMI) project that aims to create a framework for access and reutilization of clinical tria